作者:Jack J. Chen、Derek C. Cole、Greg Ciszewski、Kimberly Crouse、John W. Ellingboe、Pawel Nowak、Gregory J. Tawa、Gabriel Berstein、Wei Li
DOI:10.1016/j.bmcl.2009.11.058
日期:2010.1
cells including granulocytes, mast cells and macrophages via a specific GPCR, the C5a receptor (C5aR). Inhibition of C5a/C5aR interaction has been shown to be efficacious in several animal models of autoimmune diseases, including RA, SLE and asthma. This account reports the discovery of a new class of C5aR antagonists through high-throughput screening. The lead compounds in this series are selective and
C5a是补体级联反应的终产物,可通过特异性GPCR C5a受体(C5aR)激活并吸引包括粒细胞,肥大细胞和巨噬细胞在内的炎症细胞。在几种自身免疫性疾病的动物模型中,包括RA,SLE和哮喘,已证明C5a / C5aR相互作用的抑制是有效的。该报道报道了通过高通量筛选发现了新型的C5aR拮抗剂。该系列中的先导化合物具有选择性,能以纳摩尔浓度阻断人中性粒细胞中C5a的结合,C5a促进的钙通量。